BCII BCII Enterprises Inc (PK)

Genzyme and Bone Care International Announce Completion of Hart-Scott-Rodino Review CAMBRIDGE, Mass. and MADISON, Wis., June 15 /PRNewswire-FirstCall/ -- Genzyme Corporation (NASDAQ:GENZ) and Bone Care International, Inc. (NASDAQ:BCII) announced today that the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the proposed merger of Genzyme and Bone Care. As announced on May 4, 2005, Genzyme and Bone Care have signed a definitive merger agreement under which Genzyme will acquire Bone Care in an all cash transaction valued at $33.00 per fully diluted share. The transaction remains subject to approval by Bone Care's shareholders at a meeting on June 30, and other customary closing conditions. About Genzyme One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Founded in 1981, Genzyme has grown from a small start-up to a diversified enterprise with annual revenues exceeding $2 billion and more than 7,000 employees in locations spanning the globe. With many established products and services helping patients in more than 80 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopedics, cancer, transplant and immune diseases, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as heart disease and other areas of unmet medical need. About Bone Care Bone Care is a specialty pharmaceutical company engaged in the discovery, development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life- threatening diseases. The company's current commercial and therapeutic focus is in nephrology, utilizing Hectorol, a novel vitamin D hormone therapy, to treat secondary hyperparathyroidism in patients with moderate to severe chronic kidney disease and end-stage renal disease. In addition to chronic kidney disease, the company is developing vitamin D hormone therapies to treat hyperproliferative disorders such as cancer and psoriasis. Genzyme's press releases and other company information are available at http://www.genzyme.com/ and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-703-797-1866 outside the United States. Media Contact, Genzyme Investor Contact, Genzyme Dan Quinn Kristen Galfetti (617) 768-6849 (617) 768-6563 Media Contact, Bone Care International Brian Hayden (608) 662-7800 DATASOURCE: Genzyme Corporation CONTACT: Dan Quinn, Media Contact, +1-617-768-6849, or Kristen Galfetti, Investor Contact, +1-617-768-6563, both of Genzyme; or Brian Hayden Media Contact of Bone Care International, +1-608-662-7800 Web site: http://www.genzyme.com/ Company News On-Call: http://www.prnewswire.com/comp/104284.html

Copyright